GlassScriptPhysician profile
Nilesh L Vora
NPI 1790976363
$25,381.50
in general payments reported to CMS, 2019-2025
52 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,081 · 2020: $616 · 2021: $2,574 · 2022: $1,180 · 2023: $1,103 · 2024: $1,346 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $4,346 · Travel and Lodging: $1,044 · Education: $20.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,520.00 |
| Food and Beverage | $4,345.85 |
| Travel and Lodging | $1,043.99 |
| Education | $20.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13,220.84 | 2021-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astrazeneca Pharmaceuticals LP | $4,098.78 | 2019-2025 | Tagrisso, Enhertu |
| Regeneron Healthcare Solutions, INC. | $2,024.78 | 2021-2024 | Libtayo |
| Janssen Biotech, INC. | $1,031.14 | 2019-2025 | Tecvayli, Darzalex, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $895.87 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $357.66 | 2022-2025 | Tecentriq, Polivy, Itovebi |
| Celgene Corporation | $351.68 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Amgen INC. | $313.36 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Tempus Ai, INC | $231.18 | 2024 | Xt Cdx |
| Incyte Corporation | $210.44 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Novartis Pharmaceuticals Corporation | $195.00 | 2019-2025 | |
| Medtronic, INC. | $167.20 | 2022 | |
| Dendreon Pharmaceuticals LLC | $147.91 | 2024 | Provenge |
| Janssen Scientific Affairs, LLC | $140.53 | 2022 | |
| Beone Medicines USA, INC. | $132.85 | 2025 | Brukinsa |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilesh Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.